What are ivermectin's blood plasma detection windows after a single oral dose?

Checked on December 16, 2025
Disclaimer: Factually can make mistakes. Please verify important information or breaking news. Learn more.

This fact-check may be outdated. Consider refreshing it to get the most current information.

Executive summary

Single oral ivermectin doses reach peak plasma concentrations within about 4–5 hours and have reported elimination half-lives ranging roughly from 12 to 80 hours depending on the study and assay; many clinical studies sample plasma up to 72 hours after dosing because concentrations drop toward assay limits by then [1] [2] [3]. Detection sensitivity depends on assay lower limits (commonly ~1 ng/mL to ~0.97 ng/mL), so “detection window” varies with dose, matrix (plasma vs capillary/whole blood), and analytic method [4] [5] [6].

1. How soon after a single oral dose ivermectin is detectable and when it peaks

Ivermectin appears rapidly in plasma after oral administration and reaches peak concentrations at approximately 4 hours in most contemporary reports (one classic onchocerciasis study reported Tmax ≈5.2 h) — the usual clinical estimate is about 4–5 hours post-dose [1] [2]. Studies therefore routinely collect multiple samples in the first 12 hours to capture absorption and Cmax [3].

2. What “half‑life” and elimination tell us about detectability

Reported elimination half‑lives for ivermectin vary across studies and populations: older HPLC work reported half‑lives near 12–13 hours in small dosing studies (6–12 mg) while other work and reviews cite mean half‑lives in a broader range (about 25–80 h), reflecting different assays, populations, and possible enterohepatic recirculation [5] [1] [2]. Longer half‑life estimates correspond to prolonged low‑level exposure, but the practical detection window in plasma is constrained both by assay sensitivity and drug distribution into tissues [4] [1].

3. Typical sampling windows used by clinical studies

Because many investigators expect concentrations to fall substantially by 72 hours, clinical PK sampling is often truncated at 72 h after a single dose; several bioequivalence and PK trials therefore collect samples up to 72 h (with dense early sampling and additional late points at 48–72 h) [3]. Population PK work has modeled concentration–time curves beyond these points but initial clinical detection is normally focused within the first 3 days [7] [8].

4. How assay sensitivity shifts the detection window

Analytical methods vary: classic HPLC‑fluorescence assays reported lower limits of about 1 ng/mL and detected ivermectin up to 56–72 h after single doses of 6–12 mg [5]. Modern LC‑MS/MS methods validated in recent reports achieve quantification ranges from about 0.97 ng/mL up to several hundred ng/mL and therefore can detect lower concentrations in small plasma volumes, potentially extending practical detection compared with older methods [4] [6].

5. Matrix matters — plasma, whole blood and capillary samples differ

Ivermectin is lipophilic and distributes into tissues and skin; plasma and whole‑blood concentrations can differ and capillary blood (what mosquitoes encounter) sometimes shows different exposure than venous plasma, which affects interpretation of “detectable” levels for different purposes (therapeutic monitoring vs vector‑lethal effects). Population PK studies explicitly relate plasma and dried blood spot (DBS) results because matrix selection changes concentration profiles and detection windows [4] [9] [8] [1].

6. Dose and clinical context change windows

Reported Cmax values scale with dose: one onchocerciasis study of 150 µg/kg reported Cmax ≈52 ng/mL (patients) with Tmax 5.2 h and half‑life 35 h, and other volunteer studies at similar dosing report Cmax near ~40 ng/mL at ~4 h [2] [1]. Higher doses and formulations that increase initial exposure will lengthen the time concentrations remain above an assay’s lower limit; conversely, low single doses may become undetectable by 48–72 h with standard assays [2] [5].

7. Uncertainties, competing interpretations and limitations of existing reports

Available sources show heterogeneity: half‑life estimates span ~12–80 h [5] [1], detection durations depend on analytic lower limits [5] [4], and tissue redistribution or enterohepatic recirculation can cause secondary rises or prolonged low exposures seen in some studies [2] [1]. Population PK models attempt to reconcile these differences but note remaining uncertainty in real‑world variability, body composition effects, and matrix conversions [7] [8].

8. Practical takeaway for clinicians, researchers and forensic testing

Expect ivermectin to be readily detectable in plasma within hours of an oral dose, with Cmax near 4–5 h. With common analytical limits (~1 ng/mL) and typical single doses, plasma concentrations are usually measurable for at least 24–72 h; specific detection beyond that depends on dose, matrix, individual pharmacokinetics, and the sensitivity of the assay used [2] [5] [3] [6].

If you want, I can extract specific reported Cmax, Tmax and half‑life values from individual studies (dose by dose) in the cited literature above.

Want to dive deeper?
What is the pharmacokinetic half-life of oral ivermectin in humans?
How long does ivermectin remain detectable in plasma after standard single-dose treatment?
Which factors (age, weight, liver function) affect ivermectin plasma clearance?
What analytical methods and detection limits are used to measure ivermectin in blood?
How do ivermectin plasma levels correlate with efficacy and toxicity for parasitic infections?